According to the International Agency for Research on Cancer (IARC), the global burden of cancer in 2020 reached19.3 million cases and 10 million cancer deaths. Furthermore, according to the American Cancer Society, by 2040, the global burden of cancer will reach 27.5 million cases and 16.3 million cancer deaths.
The industry players are focusing on new product development, obtaining product approvals from the regulatory bodies for more penetration in the global host cell protein testing market. For example, in June 2019, Cygnus Technologies (US) broadened its service offerings for HCP analysis with its Mass Spec Services, which will be able to detect and quantify HCPs. Furthermore, the key players are involved in new product launches, strategic agreements, and joint ventures to augment their market positions. For instance, in August 2019, Cygnus Technologies announced a strategic partnership with Bio-Techne (US)to quantify Chinese hamster ovary host cell proteins (CHO-HCP) on the ProteinSimple Ella immunoassay platform. Furthermore, in November 2020, Thermo Fisher Scientific (US) had collaborated with Northeastern University (US) to enhance its analytical capabilities and innovate in areas like monoclonal antibodies, gene, and cell therapies, where HCP testing is required
According to MRFR analysis, the global host cell protein testing market is expected to register a CAGR of~5.7% from 2021 to 2027.
The global host cell protein (HCP) testing market is driven by several factors, such as developments in the biopharmaceutical field and growing R&D activities. Furthermore, the technological advancements in the HCP testing products will drive the market. Rising chronic diseases such as cancer are driving more R&D efforts to find viable treatments, contributing to market growth.
The global host cell protein testing market has been segmented into type and end user.
By type, the market has been segmented into PCR-based assays, ELISA-based assays, and others. The ELISA-based assays segment is expected to hold the largest share of the market in 2020 as it is considered the gold standard for HCP testing.
Based on end users, the market has been segmented into Contract Research Organizations (CROs), biopharmaceutical companies, and others. The biopharmaceutical companies segment held the largest segment share in 2020because of the extensive R&D efforts and company funding to develop new therapeutics and utilization of HCP testing in the process.
Some of the key market players areEnzo Life Sciences, Inc. (US), Cygnus Technologies Inc. (US), BioGenes GmbH (Germany), Cytiva (US), Cisbio Bioassays (France), Molecular Devices (US), Thermo Fisher Scientific (US), Charles River (US), Bio-Rad Laboratories (US), and ForteBio (Pall) (US)